Dermira (NASDAQ:DERM) is up 9% premarket on light volume as buying ripples out from AbbVie’s bid for Allergan.
Its top drug is Obrexza (glycopyrronium) for primary axillary hyperhidrosis (excessive underarm sweating), approved in the U.S. a year ago.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.